PortalPublikationenHepatobiliary MR contrast agents in hypovascular hepatocellu...

Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma

Standard

Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. / Motosugi, Utaroh; Bannas, Peter; Sano, Katsuhiro; Reeder, Scott B.

in: J MAGN RESON IMAGING, Jahrgang 41, Nr. 2, 02.2015, S. 251-65.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Motosugi, U, Bannas, P, Sano, K & Reeder, SB 2015, 'Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma', J MAGN RESON IMAGING, Jg. 41, Nr. 2, S. 251-65. https://doi.org/10.1002/jmri.24712

APA

Motosugi, U., Bannas, P., Sano, K., & Reeder, S. B. (2015). Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. J MAGN RESON IMAGING, 41(2), 251-65. https://doi.org/10.1002/jmri.24712

Vancouver

Motosugi U, Bannas P, Sano K, Reeder SB. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. J MAGN RESON IMAGING. 2015 Feb;41(2):251-65. https://doi.org/10.1002/jmri.24712

Bibtex

@article{8abdc0075e444b52813fa3ded7695703,
title = "Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) develops via multistep hepatocarcinogenesis, during which hypovascular/early HCC precedes the typical hypervascular HCC. The hypovascular HCC lacks the typical hallmark imaging features of HCC, such as late arterial phase enhancement and portal venous washout, limiting early detection using conventional extracellular contrast agents for dynamic magnetic resonance imaging (MRI) or computed tomography (CT) imaging. In recent years, gadolinium-based contrast agents with hepatobiliary uptake have garnered interest from radiologists and hepatologists due to their potential for improved detection of HCC during hepatobiliary phase MRI. Lesions with reduced or absent hepatocyte function appear hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI. This behavior can be exploited for earlier detection of hypovascular HCC. This review describes the general characteristics and advantages of gadoxetic acid for the diagnosis of HCC with a particular focus on hypovascular/early HCC.",
keywords = "Carcinoma, Hepatocellular, Contrast Media, Gadolinium DTPA, Humans, Liver Neoplasms, Magnetic Resonance Imaging, Journal Article, Review",
author = "Utaroh Motosugi and Peter Bannas and Katsuhiro Sano and Reeder, {Scott B}",
note = "{\textcopyright} 2014 Wiley Periodicals, Inc.",
year = "2015",
month = feb,
doi = "10.1002/jmri.24712",
language = "English",
volume = "41",
pages = "251--65",
journal = "J MAGN RESON IMAGING",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma

AU - Motosugi, Utaroh

AU - Bannas, Peter

AU - Sano, Katsuhiro

AU - Reeder, Scott B

N1 - © 2014 Wiley Periodicals, Inc.

PY - 2015/2

Y1 - 2015/2

N2 - Hepatocellular carcinoma (HCC) develops via multistep hepatocarcinogenesis, during which hypovascular/early HCC precedes the typical hypervascular HCC. The hypovascular HCC lacks the typical hallmark imaging features of HCC, such as late arterial phase enhancement and portal venous washout, limiting early detection using conventional extracellular contrast agents for dynamic magnetic resonance imaging (MRI) or computed tomography (CT) imaging. In recent years, gadolinium-based contrast agents with hepatobiliary uptake have garnered interest from radiologists and hepatologists due to their potential for improved detection of HCC during hepatobiliary phase MRI. Lesions with reduced or absent hepatocyte function appear hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI. This behavior can be exploited for earlier detection of hypovascular HCC. This review describes the general characteristics and advantages of gadoxetic acid for the diagnosis of HCC with a particular focus on hypovascular/early HCC.

AB - Hepatocellular carcinoma (HCC) develops via multistep hepatocarcinogenesis, during which hypovascular/early HCC precedes the typical hypervascular HCC. The hypovascular HCC lacks the typical hallmark imaging features of HCC, such as late arterial phase enhancement and portal venous washout, limiting early detection using conventional extracellular contrast agents for dynamic magnetic resonance imaging (MRI) or computed tomography (CT) imaging. In recent years, gadolinium-based contrast agents with hepatobiliary uptake have garnered interest from radiologists and hepatologists due to their potential for improved detection of HCC during hepatobiliary phase MRI. Lesions with reduced or absent hepatocyte function appear hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI. This behavior can be exploited for earlier detection of hypovascular HCC. This review describes the general characteristics and advantages of gadoxetic acid for the diagnosis of HCC with a particular focus on hypovascular/early HCC.

KW - Carcinoma, Hepatocellular

KW - Contrast Media

KW - Gadolinium DTPA

KW - Humans

KW - Liver Neoplasms

KW - Magnetic Resonance Imaging

KW - Journal Article

KW - Review

U2 - 10.1002/jmri.24712

DO - 10.1002/jmri.24712

M3 - SCORING: Journal article

C2 - 25104398

VL - 41

SP - 251

EP - 265

JO - J MAGN RESON IMAGING

JF - J MAGN RESON IMAGING

SN - 1053-1807

IS - 2

ER -